University of Southern Mississippi
University of Southern Mississippi sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diet, with 1 trials.
Trial Pipeline
7 total, page 1 of 1
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
NCT05997862
The Okla Achokma Project
NCT06633939
Ketone Esters for Appetite, Cognition, and Cardiovascular Function in Individuals With Obesity and Insulin Resistance
NCT05651243
Nutrition360: Moving to Integrated and Holistic Disease Prevention Among Underserved Mississippians
NCT06286618
Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi
NCT05425290
Telenutrition Center: Examining the Implementation of Behavioral Therapy for Obesity
NCT03855566
Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks
NCT03375099
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What the Pipeline for University of Southern Mississippi Shows
According to the ClinicalTrials.gov registry, University of Southern Mississippi is linked to 7 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting, about 14% of the sponsor's indexed portfolio, and 5 are already marked complete, representing roughly 71% of the total.
The phase mix for University of Southern Mississippi reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for University of Southern Mississippi is Diet with 1 linked trial, and 5 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.